Chu Tivoli

La Louvière 7100

3 studies enrolling now · 12 studies all time

What they study most

Anhedonia, Atrial Fibrillation, BMM, Bone Marrow Mastocytosis, Brady Tachy Syndrome, Depressive Disorder, Major, Diabetes Mellitus, Type 2, Hypertension, ISM, Indolent Systemic Mastocytosis, Intracerebral Hemorrhage, Ischemic Stroke; Ischemic Attack, Transient

Studies at this site

• (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis — Recruiting now
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight — Recruiting now
• A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis — Running, not enrolling
• A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant — Stopped early
• A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec — Completed
• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) — Stopped early
• A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis — Completed
• The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial — Completed
• Prevention of Atrial Arrhythmia in Patients Without Atrioventricular (AV) Conduction Disease — Completed